Suvorexant
Brand name: Belsomra
Rank #290 of 500 drugs by total cost
$40.7M
Total Cost
87,327
Total Claims
$40.7M
Total Cost
4,036
Prescribers
$466
Cost per Claim
5,509
Beneficiaries
94,124
30-Day Fills
$10K
Avg Cost/Provider
22
Avg Claims/Provider
About Suvorexant
Suvorexant (sold as Belsomra) was prescribed 87,327 times by 4,036 Medicare Part D providers in 2023, costing the program $40.7M. At $466 per claim, this is a moderately priced medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 287 | Daptomycin (Daptomycin) | $41.2M | 41,245 |
| 288 | Pitavastatin Calcium (Livalo) | $40.8M | 69,636 |
| 289 | Bromfenac Sodium (Prolensa) | $40.8M | 121,284 |
| 290 | Suvorexant (Belsomra) | $40.7M | 87,327 |
| 291 | Atogepant (Qulipta) | $40.7M | 32,955 |
| 292 | Obeticholic Acid (Ocaliva) | $40.6M | 4,131 |
| 293 | Doxycycline Hyclate (Doxycycline Hyclate) | $40.5M | 2,023,357 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology